These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 10284382)

  • 1. Hospital policies on pharmaceutical sales representatives' activities.
    Oddis JA
    Resid Staff Physician; 1987 Sep; 33(10):8. PubMed ID: 10284382
    [No Abstract]   [Full Text] [Related]  

  • 2. National survey of hospital policies on pharmaceutical sales representatives' activities.
    Thomas J
    Am J Hosp Pharm; 1987 Jun; 44(6):1334-40. PubMed ID: 3618609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hospital pharmacists seek to control sales rep activities.
    Alt SJ
    Hosp Mater Manage; 1992 Apr; 17(4):2, 16. PubMed ID: 10170987
    [No Abstract]   [Full Text] [Related]  

  • 4. National survey of recent changes in hospital policies on pharmaceutical sales representatives' activities.
    Thomas J
    Am J Hosp Pharm; 1989 Mar; 46(3):565-9. PubMed ID: 2719042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical sales representatives.
    Tatro DS; Miller RF
    Hosp Formul; 1983 Apr; 18(4):466. PubMed ID: 10259513
    [No Abstract]   [Full Text] [Related]  

  • 6. Monitoring the hospital activities of medical service representatives.
    Willcox GS; Mahoney CD; Jeffrey LP
    Am J Hosp Pharm; 1983 Jun; 40(6):989-91. PubMed ID: 6869405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One hospital's rules for pharmaceutical sales representatives.
    Hethcox JM
    Hosp Formul; 1977 Feb; 12(2):112, 115-6. PubMed ID: 10305394
    [No Abstract]   [Full Text] [Related]  

  • 8. Factors associated with physicians' reliance on pharmaceutical sales representatives.
    Anderson BL; Silverman GK; Loewenstein GF; Zinberg S; Schulkin J
    Acad Med; 2009 Aug; 84(8):994-1002. PubMed ID: 19638762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug detailing in the hospital: background for policy development.
    Chan J; Einarson T
    Can J Hosp Pharm; 1991 Jun; 44(3):161-6. PubMed ID: 10112744
    [No Abstract]   [Full Text] [Related]  

  • 10. Guidelines for pharmacists and the pharmaceutical industry. The Canadian Society of Hospital Pharmacists.
    Dimens Health Serv; 1990 Nov; 67(8):14-6. PubMed ID: 2276520
    [No Abstract]   [Full Text] [Related]  

  • 11. Medicine's "gray market"': why alarm bells are ringing.
    Gest T; Lanier LK
    US News World Rep; 1985 Dec; 99(23):52. PubMed ID: 10274713
    [No Abstract]   [Full Text] [Related]  

  • 12. Minimizing the influence of drug marketing.
    Hester FG
    Hospitals; 1990 Aug; 64(15):80. PubMed ID: 2373503
    [No Abstract]   [Full Text] [Related]  

  • 13. Hospital-based training for pharmaceutical manufacturers' representatives.
    Phillips DJ; Smith JE
    Am J Hosp Pharm; 1983 Oct; 40(10):1661-3. PubMed ID: 6638029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [For the increase of qualification of engineering cadres for the chemical and pharmaceutical industry].
    Blazek J
    Cesk Farm; 1974 Dec; 23(10):397-9. PubMed ID: 4455399
    [No Abstract]   [Full Text] [Related]  

  • 15. Nurse prescribers' interactions with and perceptions of pharmaceutical sales representatives.
    Clauson KA; Khanfar NM; Polen HH; Gibson F
    J Clin Nurs; 2009 Jan; 18(2):228-33. PubMed ID: 19120751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reporting drug product defects--JCAHO.
    Hoffmann RP
    Hosp Pharm; 1989 Feb; 24(2):143-4. PubMed ID: 10318199
    [No Abstract]   [Full Text] [Related]  

  • 17. Other viewpoints on the effects of cost controls.
    Davis NM
    Hosp Pharm; 1983 Aug; 18(8):400-5, 409. PubMed ID: 10261790
    [No Abstract]   [Full Text] [Related]  

  • 18. Current status of pharmaceutical services in hospitals.
    Oddis JA
    Resid Staff Physician; 1986 Dec; 32(12):15, 18. PubMed ID: 10279930
    [No Abstract]   [Full Text] [Related]  

  • 19. Quality control of drugs.
    Whittet TD
    J Ir Med Assoc; 1968 Oct; ():Suppl 1:15-9. PubMed ID: 5701292
    [No Abstract]   [Full Text] [Related]  

  • 20. Shades of gray. Secondary drug distributors raise questions.
    Lee J
    Mod Healthc; 2011 Oct; 41(41):10, 12. PubMed ID: 22111494
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.